Quick Overview: The second of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference. The second of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. The first of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference.
Agdd 2024 D2s08 Q A - Detailed Overview & Context
The second of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference. The second of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. The first of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference. This presentation provided an overview of the current use of Comparative Use Human Factors (CUHF) studies to support various ... This presentation explained factors that could impact first-cycle bioequivalence (BE) adequacy based on observed BE ... The first of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference.
The final Q&A discussion panel from day two of the Advancing Generic Drug Development Conference. ***No Timestamps*** ... The final Q&A discussion panel from day one of the Advancing Generic Drug Development Conference. ***No Timestamps*** ... This presentation identified recent product-specific guidance (PSG) documents that include detailed language regarding the use ... This presentation described content and format requirements for composition statements of drug products and explained what to ... The third of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. This presentation discussed the ANDA landscape for topical products applied to the skin and identified challenges associated ...
Closing remarks from day two of the Advancing Generic Drug Development Conference delivered by Dr. Robert Lionberger. This presentation explored general constraints in dry powder inhaler (DPI) formulation and manufacturing, while discussing ... This presentation discussed the complexity of generic oligonucleotides and RLD-equivalence considerations, while reviewing key ... This presentation examined In Vitro Release Testing (IVRT) for drug products containing nanomaterials, with a specific focus on ... Closing remarks from day one of the Advancing Generic Drug Development Conference delivered by Dr. Sau (Larry) Lee. FDA experts demonstrate the FDA's Generic Drug User Fee Amendments (GDUFA) Science and Research Program's ...
This presentation provided key principles for comparative analyses (CA) and established understanding of essential CA ... This presentation informed attendees about FDA's laboratory support for inhalation drug assessment and the research efforts ...
